<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
42976-121-02
</NDCCode>
<PackageDescription>
1 VIAL in 1 CARTON (42976-121-02) > 3 mL in 1 VIAL
</PackageDescription>
<NDC11Code>
42976-0121-02
</NDC11Code>
<ProductNDC>
42976-121
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Atryn
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Antithrombin Recombinant
</NonProprietaryName>
<DosageFormName>
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
</DosageFormName>
<RouteName>
INTRAVENOUS
</RouteName>
<StartMarketingDate>
20090506
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
BLA
</MarketingCategoryName>
<ApplicationNumber>
BLA125284
</ApplicationNumber>
<LabelerName>
rEVO Biologics, Inc.
</LabelerName>
<SubstanceName>
ANTITHROMBIN ALFA
</SubstanceName>
<StrengthNumber>
1750
</StrengthNumber>
<StrengthUnit>
[iU]/mL
</StrengthUnit>
<Pharm_Classes>
Decreased Coagulation Factor Activity [PE], Factor Xa Inhibitors [MoA], Recombinant Antithrombin [EPC], Thrombin Inhibitors [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2022-06-23
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20221231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
20090506
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage>
N
</SamplePackage>
</NDC>